Intervention Protocol

You have free access to this content

Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants

  1. Kiran More1,*,
  2. Gayatri Athalye-Jape1,
  3. Shripada C Rao2,
  4. Sanjay K Patole3

Editorial Group: Cochrane Neonatal Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 2 MAR 2013

DOI: 10.1002/14651858.CD010531


How to Cite

More K, Athalye-Jape G, Rao SC, Patole SK. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD010531. DOI: 10.1002/14651858.CD010531.

Author Information

  1. 1

    Princess Margaret Hospital and King Edward Hospital, Department of Neonatology, Subiaco, Western Australia, Australia

  2. 2

    King Edward Memorial Hospital for Women and Princess Margaret Hospital for Children, Centre for Neonatal Research and Education, Perth, Western Australia, Australia

  3. 3

    King Edward Memorial Hospital, School of Paediatrics and Child Health, School of Women's and Infant's Health, University of Western Australia, Perth, Western Australia, Australia

*Kiran More, Department of Neonatology, Princess Margaret Hospital and King Edward Hospital, Roberts Road, Subiaco, Western Australia, 6008, Australia. drkiranmore@yahoo.com. kiran.more@health.wa.gov.au.

Publication History

  1. Publication Status: New
  2. Published Online: 31 MAY 2013

SEARCH

References

Additional references

Abman 2007
Abman 2009
Allen 1993
  • Allen SW,  Chatfield BA,  Koppenhafer SA,  Schaffer MS,  Wolfe RR,  Abman SH. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. American Review of Respiratory Disease 1993;148(2):519-22.
Ambalavanan 2005
  • Ambalavanan N, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatric Research 2005;57(5 Pt 1):631-6.
Barton 2008
Beghetti 2009
  • Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Current Vascular Pharmacology 2009;7(2):225-33.
Dakshinamurti 2005
Davenport 2006
  • Davenport AP, Maguire JJ. Endothelin. Handbook of Experimental Pharmacology 2006;176 Pt 1:295-329.
de Lagausie 2005
Dhillon 2012
Egger 1997
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
Endo 2001
  • Endo A,  Ayusawa M,  Minato M,  Takada M,  Takahashi S,  Harada K. Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. European Journal of Pediatrics 2001;160(4):217-22.
Galie 2004
Geiger 2006
  • Geiger R, Pajk W, Neu N, Maier S, Kleinsasser A, Fratz S, et al. Tezosentan decreases pulmonary artery pressure and improves survival rate in an animal model of meconium aspiration. Pediatric Research 2006;59(1):147-50.
Geiger 2008
  • Geiger R, Kleinsasser A, Meier S, Neu N, Pajk W, Fischer V, et al. Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration. Intensive Care Medicine 2008;34(2):368-76.
Gersony 1984
Giaid 1993
  • Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New England Journal of Medicine 1993;328(24):1732-9.
Goissen 2008
  • Goissen C, Ghyselen L, Tourneux P, Krim G, Storme L, Bou P, et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. European Journal of Pediatrics 2008;167(4):437-40.
Greenough 2005
  • Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatric Respiratory Reviews 2005;6(2):111-6.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hirono 2010
  • Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, et al. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. Journal of Thoracic and Cardiovascular Surgery 2010;140(2):346-51.
Konduri 2009
Krishnan 2008
Kuo 2001
  • Kuo CY. Endothelin-A receptor antagonist prevents neonatal pulmonary hypertension in meconium aspiration in piglets. Journal of the Formosan Medical Association 2001;100(6):420-3.
La 1995
Lakshminrusimha 1999
Levy 2005
  • Levy M, Maurey C, Dinh-Xuan AT, Vouhe P, Israel-Biet D. Developmental expression of vasoactive and growth factors in human lung. Role in pulmonary vascular resistance adaptation at birth. Pediatric Research 2005;57(5 Pt 2):21R-5R.
Levy 2005a
  • Levy M, Maurey C, Chailley-Heu B, Martinovic J, Jaubert F, Israel-Biet D. Developmental changes in endothelial vasoactive and angiogenic growth factors in the human perinatal lung. Pediatric Research 2005;57(2):248-53.
Liu 2013
Luscher 2000
  • Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102(19):2434-40.
Nakwan 2009
Nemoto 2007
  • Nemoto S, Yoshimura S, Matsumura M, Nishimura K. An initial experience of endotherine-1 dual-receptor blockade in the treatment of sustained pulmonary hypertension early after congenital cardiac surgery in infancy. Kyobu Geka. The Japanese Journal of Thoracic Surgery 2007;60(6):453-6.
O'Callaghan 2011
  • O'Callaghan DS, Savale L, Montani D, Jais X, Sitbon O, Simonneau G, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews. Cardiology 2011;8(9):526-38.
Oishi 2011
Pearl 1999
  • Pearl JM, Wellmann SA, McNamara JL, Lombardi JP, Wagner CJ, Raake JL, et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Annals of Thoracic Surgery 1999;68(5):1714-21; discussion 1721-2.
Peng 2003
  • Peng J, Ladino J, Hehre D, Bancalari E, Suguihara E. Effects of a selective endothelin A (ETA) receptor antagonist on GBS-induced pulmonary hypertension in newborn piglets. Pediatric Academic Societies’ Annual Meeting. 2003; Vol. E-PAS:2443.
Persson 2009
Radicioni 2011
  • Radicioni M, Bruni A, Camerini P. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use. European Journal of Pediatrics 2011;170(8):1075-8.
Rao 2010
  • Rao S, Bartle D, Patole S. Current and future therapeutic options for persistent pulmonary hypertension in the newborn. Expert Review of Cardiovascular Therapy 2010;8(6):845-62.
Roberts 1997
  • Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. New England Journal of Medicine 1997;336(9):605-10.
Rosenberg 1993
  • Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. Journal of Pediatrics 1993;123(1):109-14.
Shah 2011
Shao 2011
Stathopoulos 2011
  • Stathopoulos E, Rolland PH, Héry G, de Magnée C, Paut O, Couchot E, et al. Acute effect of a dual ETA-ETB receptor antagonist on pulmonary arterial vasculature in preterm lamb fetuses with surgically induced diaphragmatic hernia. Pediatric Surgery International 2011;27(3):295-301.
Stayer 2010
  • Stayer SA, Liu Y. Pulmonary hypertension of the newborn. Best Practice and Research Clinical Anaesthesiology 2010;24(3):375-86.
Steinhorn 2010
Torre Amione 2003
  • Torre-Amione G,  Young JB,  Colucci WS,  Lewis BS,  Pratt C,  Cotter G,  et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology 2003;42(1):140-7.
Yanagisawa 1988